Biotech Values

[DewDiligence]

…if Roche wasn't involved and a smaller company was in control of the drug, they would have gone into phase 2 with the wrong dose and it would have been a failed drug.

You’ve hit on the crux of this series of articles from an investment standpoint. I wonder if the NYT author was able to make this connection.